Breaking News Headlines Today | Ground News

See every side of every news story

ajmc.com image

News from ajmc.com

ajmc.com’s aggregated media bias check is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, All Sides, and Media Bias/Fact Check.

ajmc.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about ajmc.com

Where is ajmc.com located?ajmc.com's Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ajmc.com News

Trump Announces Cost Cuts to Weight Loss Drugs — REUTERS / pwu404

GLP-1 · United States

Trump Announces Cost Cuts to Weight Loss Drugs

58% Center coverage: 317 sources

U.S. President Donald Trump announced agreements with pharmaceutical companies Novo Nordisk and Eli Lilly to reduce prices for their obesity drugs Wegovy and Zepbound, respectively, including $50 monthly copays for Medicare patients starting mid-2026 and expanded coverage for those with severe obesity.See the Story

FDA Reverses Decades-Old Warning on Hormone Therapy Products for Menopause — REUTERS / pwu404

FDA · United States

FDA Reverses Decades-Old Warning on Hormone Therapy Products for Menopause

51% Center coverage: 203 sources

FDA removes black box warning on hormone therapy, reflecting new science on menopause, heart health, and evolving views on women’s care.See the Story

Two Drugs Approved for NPM1-Mutated Leukemia

United States · United States

Two Drugs Approved for NPM1-Mutated Leukemia

80% Center coverage: 5 sources

(MedPage Today) -- The FDA has approved two targeted menin inhibitors for the treatment of relapsed/refractory NPM1-mutated acute myeloid leukemia (AML). Ziftomenib (Komzifti) was approved on Thursday for adults with relapsed/refractory NPM1-mutated...See the Story

Breaking News Topics Related to ajmc.com